STOCKS TELEGRAPH

Tag: Scinai Immunotherapeutics Stock

  • Extended Session Boost For Scinai Immunotherapeutics (SCNI) Stock

    Extended Session Boost For Scinai Immunotherapeutics (SCNI) Stock

    Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) experienced a significant extended-session rally after highlighting recognition for its breakthrough science. SCNI stock advanced 14.59% to $2.35, following the announcement that one of its key collaborators earned a distinguished award in dermatology research.

    Prestigious Award for Pioneering Pemphigus Research

    Scinai Immunotherapeutics disclosed that Dr. Roberta Lotti, a lead scientist at Pincell Srl, received the esteemed “Oscar of Italian Dermatology” from SIDeMaST, the Italian Society of Dermatology and Venereology.

    The honor, awarded in the Immunopathology and Cutaneous Allergies category, recognized her groundbreaking study, “Blocking Soluble Fas Ligand Ameliorates Pemphigus: PC111 Efficacy in Ex-Vivo Human Pemphigus Models.”

    The research focuses on PC111, a first-in-class anti-Fas Ligand monoclonal antibody. Scinai holds a strategic option agreement to acquire Pincell, the biotech company developing this innovative treatment.

    PC111: A Novel Approach to Severe Autoimmune Skin Diseases

    PC111 targets the soluble form of Fas Ligand (sFasL), a critical driver of Pemphigus Vulgaris (PV) and Stevens-Johnson/Toxic Epidermal Necrolysis (SJS/TEN)—serious autoimmune and drug-induced blistering disorders with high morbidity and mortality rates.

    Earlier studies by Pincell demonstrated that soluble FasL triggers keratinocyte apoptosis leading to acantholysis. Dr. Lotti’s award-winning paper confirmed PC111’s mechanism of action in human pemphigus models, showing that it inhibits blister formation by preventing apoptosis—representing a differentiated, non-immunosuppressive approach to treatment.

    Potential for Clinical Use and Strategic Consequences for Scinai

    The local method of action of PC111 tackles the disease process directly, potentially decreasing long-term adverse effects, in contrast to traditional medicines that rely on systemic immunosuppression. Instead of only managing symptoms, this breakthrough represents a step toward disease-modifying treatments.

    The acknowledgement supports Scinai’s plan to safeguard Pincell’s pipeline for autoimmune dermatology. PC111 is positioned as a high-value asset in Scinai’s immunology portfolio due to its promising profile, faster regulatory routes, and possible orphan medication classification.

    Industry Acknowledgment

    The price was awarded during the XIV International Congress of Dermatology in Rome last month. SIDeMaST’s “Oscar of Italian Dermatology,” is one of the most prestigious awards in the area, which highlights the importance of Dr. Lotti’s work from a scientific and clinical standpoint.

    Scinai keeps developing PC111 in an effort to make it a game-changing treatment for those with severe, uncommon dermatological conditions.

  • Scinai (SCNI) Shares Climb Following Key Acquisition Progress

    Scinai (SCNI) Shares Climb Following Key Acquisition Progress

    Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) saw a substantial increase in the value of its shares today, with stock prices rising 43.55% to $3.62. The increase demonstrates rising investor trust in the transaction’s strategic importance and possible influence on the market.

    Strategic Milestone Approval

    In a significant move, Scinai Immunotherapeutics disclosed that the Italian government has approved SCNI’s option to purchase 100% of Pincell S.r.l.’s share capital and voting rights under its Golden Power legislation. Scinai Immunotherapeutics may now proceed with closing the purchase as this regulatory permission removes one of the main legal obstacles mentioned in the March 2025 option agreement.

    The authorization followed an extensive review by Italy’s Coordination Group for the exercise of special powers, based on findings from the Ministry of Health. The approval also covers licensing arrangements between Pincell and SCNI’s Polish subsidiary, Scinai Immunotherapeutics Sp. Z.O.O, for the use of Pincell’s intellectual property.

    Pincell’s Pipeline and Strategic Fit

    PC111, a completely human monoclonal antibody that targets the Fas/FasL pathway, is Pincell’s top therapeutic candidate. It is being developed to treat severe autoimmune dermatological disorders such Toxic Epidermal Necrolysis (TEN), Stevens-Johnson Syndrome (SJS), and pemphigus. Notably, PC111 has previously received the European Medicines Agency’s Orphan Drug Designation for Pemphigus, demonstrating its potential as a treatment for uncommon illnesses.

    Next Steps and Pending Conditions

    While the regulatory clearance is a pivotal achievement, Scinai Immunotherapeutics emphasized that the acquisition remains incomplete. The conclusion of a €12 million grant application made under the European Funds for a Modern Economy (FENG) program to assist PC111’s development is one of the closing requirements the firm is still pursuing. There will likely be a financial decision between mid-July and early August 2025.

    Considered a game-changer for its immunotherapeutics portfolio, Scinai Immunotherapeutics (SCNI) reiterated its intention to complete all outstanding commitments necessary to complete the transaction.

  • Scinai (SCNI) Experiences Sharp Stock Rebound In Extended Hours

    Scinai (SCNI) Experiences Sharp Stock Rebound In Extended Hours

    On Thursday, Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) saw a notable recovery in its stock performance during the extended trading session. SCNI shares surged by 9.48%, rebounding from a previous regular-session loss of 8.13%, and closed at $4.01. This significant fluctuation in stock value followed the company’s recent equity adjustments.

    Scinai Finalized The Loan Restructuring Agreement

    The European Investment Bank (EIB) and Scinai have successfully completed a loan restructuring agreement that includes changes to the parties’ current finance contract. As per the deal, 1,000 preferred shares of Scinai were exchanged for roughly EUR 26.6 million, which is equivalent to nearly $29 million, including accrued interest.

    The company’s remaining debt to the EIB has been lowered to EUR 250,000 (about $273,000) as a consequence. The balance is scheduled to maturity on December 31, 2031, and there will be no more interest charged or prepayment penalties.

    Impact on SCNI Stockholders’ Equity and Nasdaq Compliance

    Following the restructuring, SCNI has achieved a stockholders’ equity exceeding $2.5 million, meeting the Nasdaq Listing Rules’ requirements. The company anticipates receiving formal confirmation from the Nasdaq Hearing Panel regarding its compliance with the equity requirement. This development marks a significant milestone in Scinai’s efforts to stabilize its financial standing.

    Preferred Shares and Finance Contract Amendments

    The terms of the newly issued Preferred Shares, detailed in the Amended and Restated Articles of Association approved by shareholders on August 12, 2024, stipulate that each share can be converted into 364 American Depositary Shares (ADSs), representing 19.5% of the company’s fully diluted capital as of the closing date.

    Additionally, the Preferred Shares are redeemable by Scinai (SCNI) at a cumulative value of $34 million. The recent amendments to the Finance Contract also remove the requirement for variable remuneration payments previously stipulated. This restructuring and subsequent stock recovery reflect a pivotal shift in Scinai’s financial landscape, positioning the company for potential future growth and stability.